Interaction of Nε(carboxymethyl)lysine- and methylglyoxalmodified albumin with endothelial cells and macrophages

Summary

In diabetes mellitus an increased risk exists for vascular complications. A role for advanced glycation endproducts (AGEs) in the acceleration of vascular disease has been suggested. Nε(carboxymethyl)lysine (CML)- and methylglyoxal (MGO)-modified proteins have been identified as majorAGEs. The interaction of these AGEs with the human endothelial cells and macrophages was studied. Changes in adhesion molecule expression, i. e. vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin were determined by cell-bound Elisa on human endothelial cells after incubation with CML-modified albumin and MGO-modified albumin. The presence of the full-length receptor of AGEs (RAGE) and splice variants of RAGE was determined by specific RT-PCR. In addition, binding studies were performed with CML- and MGOmodified albumin to endothelial cells and P388D1 macrophages. We demonstrated that CML-albumin or MGO-albumin did not induce activation of endothelial cells as measured by the expression of adhesion molecules, while, under the same conditions, TNF-α did. No specific binding of CML-albumin and MGO-albumin on these cells was found. In contrast to endothelial cells, a specific binding of MGO-albumin to P388D1 macrophages was demonstrated, which could be competed by ligands of scavenger receptors. In human umbilical vein and microvascular endothelial cells we found the N-truncated and C-truncated splice variants of RAGE.

In conclusion, under our experimental conditions no CML- or MGO-albumin-induced increase in adhesion molecule expression was found on endothelial cells. In agreement with this, no binding of these AGEs was found to endothelial cells. The existence of splice variants of RAGE in endothelial cells might explain the lack of interaction of extracellular AGEs with these cells.

Keywords

Carboxymethyllysine - methylglyoxal - HUVECs - endothelial activation - adhesion molecules - human microvascular endothelial cells

• References

• 1 Pearson TA, Blair SN, Daniels SR. et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388-91.
• 2 Kilhovd BK, Berg TJ, Birkeland KI. et al. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999; 22: 1543-8.
• 3 Makita Z, Radoff S, Rayfield EJ. et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-42.
• 4 Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
• 5 Vlassara H, Fuh H, Makita Z. et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 1992; 89: 12043-7.
• 6 Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003; 25: 283-92.
• 7 Neeper M, Schmidt AM, Brett J. et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-5004.
• 8 Schmidt AM, Hori O, Chen JX. et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-403.
• 9 Yamagishi S, Fujimori H, Yonekura H. et al. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998; 41: 1435-41.
• 10 Park L, Raman KG, Lee KJ. et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 04: 1025-31.
• 11 Sakaguchi T, Yan SF, Yan SD. et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111: 959-72.
• 12 Wautier JL, Zoukourian C, Chappey O. et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-43.
• 13 Greten J, Kreis I, Wiesel K. et al. Receptors for advance glycation end-products (AGE) – expression by endothelial cells in non-diabetic uraemic patients. Nephrol Dial Transplant 1996; 11: 786-90.
• 14 Yonekura H, Yamamoto Y, Sakurai S. et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetesinduced vascular injury. Biochem J 2003; 370: 1097-109.
• 15 Schlueter C, Hauke S, Flohr AM. et al. Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing?. Biochim Biophys Acta 2003; 1630: 1-6.
• 16 Reddy S, Bichler J, Wells-Knecht KJ. et al. Ne-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34: 10872-8.
• 17 Kislinger T, Fu C, Huber B. et al. Ne -(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-9.
• 18 Kunt T, Forst T, Harzer O. et al. The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Exp Clin Endocrinol Diabetes 1998; 106: 183-8.
• 19 Basta G, Lazzerini G, Massaro M. et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-22.
• 20 Hui YY, McAmis WC, Baynes JW. et al. Effect of advanced glycation end products on oxidative stress in endothelial cells in culture: a warning on the use of cells studied in serum-free media. Diabetologia 2001; 44: 1310-7.
• 21 Shinohara M, Thornalley PJ, Giardino I. et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 1998; 101: 1142-7.
• 22 Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 2000; 77: S26-30.
• 23 Westwood ME, Argirov OK, Abordo EA. et al. Methylglyoxal-modified arginine residues--a signal for receptor-mediated endocytosis and degradation of proteins by monocytic THP-1 cells. Biochim Biophys Acta 1997; 1356: 84-94.
• 24 Abordo EA, Thornalley PJ. Synthesis and secretion of tumour necrosis factor-alpha by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. Immunol Lett 1997; 58: 139-47.
• 25 Abordo EA, Westwood ME, Thornalley PJ. Synthesis and secretion of macrophage colony stimulating factor by mature human monocytes and human monocytic THP-1 cells induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. Immunol Lett 1996; 53: 7-13.
• 26 Westwood ME, Thornalley PJ. Induction of synthesis and secretion of interleukin1 beta in the human monocytic THP-1 cells by human serum albumins modified with methylglyoxal and advanced glycation endproducts. Immunol Lett 1996; 50: 17-21.
• 27 Fan X, Subramaniam R, Weiss MF. et al. Methylglyoxal-bovine serum albumin stimulates tumor necrosis factor alpha secretion in RAW 264.7 cells through activation of mitogen-activating protein kinase, nuclear factor kB and intracellular reactive oxygen species formation. Arch Biochem Biophys 2003; 409: 274-86.
• 28 Maciag T, Cerundolo J, Ilsley S. et al. An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci USA 1979; 76: 5674-8.
• 29 Jaffe EA, Nachman RL, Becker CG. et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-56.
• 30 Koolwijk P, van Erck MG, de Vree WJ. et al. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996; 132: 1177-88.
• 31 Schalkwijk CG, Ligtvoet N, Twaalfhoven H. et al. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 1999; 48: 2446-53.
• 32 Millar WT, Smith JF. Protein iodination using Iodogen. Int J Appl Radiat Isot 1983; 34: 639-41.
• 33 Smith RE, MacQuarrie R. A sensitive fluorometric method for the determination of arginine using 9,10-phenanthrenequinone. Anal Biochem 1978; 90: 246-55.
• 34 Bank RA, Jansen EJ, Beekman B. et al. Amino acid analysis by reverse-phase high-performance liquid chromatography: improved derivatization and detection conditions with 9-fluorenylmethyl chloroformate. Anal Biochem 1996; 240: 167-76.
• 35 Lo TW, Westwood ME, McLellan AC. et al. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N a-acetylarginine, N a-acetylcysteine, and N a-acetyllysine, and bovine serum albumin. J Biol Chem 1994; 269: 32299-305.
• 36 Oya T, Hattori N, Mizuno Y. et al. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem 1999; 274: 18492-502.
• 37 van Dam B, van Hinsbergh VW, Stehouwer CD. et al. Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects. Cardiovasc Res 2003; 57: 563-71.
• 38 Pober JS. Endothelial activation: intracellular signaling pathways. Arthritis Res 2002; 04 (Suppl. 03) S109-S116.
• 39 Esposito C, Gerlach H, Brett J. et al. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170: 1387-407.
• 40 Schmidt AM, Yan SD, Yan SF. et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-55.
• 41 Taguchi A, Blood DC, del Toro G. et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-60.
• 42 Hofmann MA, Drury S, Fu C. et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
• 43 Yeh CH, Sturgis L, Haidacher J. et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kB transcriptional activation and cytokine secretion. Diabetes 2001; 50: 1495-504.